Barr Laboratories

BRL-N

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about BRL-N

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
October 24, 2006
(A Top Pick Sept 26/05. Down 7%.) Still likes. Down because the Wal-Mart announcement of putting price pressures on generics. Very innovative company, introducing lots of new products. Acquiring a European company to increase penetration into Europe.
Barr Laboratories (BRL-N)
October 24, 2006
(A Top Pick Sept 26/05. Down 7%.) Still likes. Down because the Wal-Mart announcement of putting price pressures on generics. Very innovative company, introducing lots of new products. Acquiring a European company to increase penetration into Europe.
Laura Wallace
Managing Director, Coleford Investment Management
Price
$52.470
Owned
Yes
PAST TOP PICK
PAST TOP PICK
August 14, 2006
(A Top Pick Sept 26/05. Up 10%.) Still likes and is continuing to buy it here. The big news is the approval of their oral contraceptive.
(A Top Pick Sept 26/05. Up 10%.) Still likes and is continuing to buy it here. The big news is the approval of their oral contraceptive.
Laura Wallace
Managing Director, Coleford Investment Management
Price
$52.320
Owned
Yes
BUY
BUY
July 20, 2006
Has come off sharply but she is still buying. There were delays in the FDA in getting some of its drugs approved. Earnings will continue to be delivered and thinks their drug will be approved. Good value.
Has come off sharply but she is still buying. There were delays in the FDA in getting some of its drugs approved. Earnings will continue to be delivered and thinks their drug will be approved. Good value.
Laura Wallace
Managing Director, Coleford Investment Management
Price
$46.370
Owned
Yes
PAST TOP PICK
PAST TOP PICK
May 17, 2006
(A Top Pick Mar 15/06. Down 22%.) Lowered its guidance by $0.01 and also received a letter from the FDA denying them an extension on a patent. Feels they can continue to grow earnings in the 15/20% range. In a good buying range now.
(A Top Pick Mar 15/06. Down 22%.) Lowered its guidance by $0.01 and also received a letter from the FDA denying them an extension on a patent. Feels they can continue to grow earnings in the 15/20% range. In a good buying range now.
Laura Wallace
Managing Director, Coleford Investment Management
Price
$49.730
Owned
Yes
TOP PICK
TOP PICK
May 3, 2006
Generic drug manufacturer. Earnings are growing in the 20/25% range. Generics are the beneficiaries of the push to control the accelerating healthcare costs in the US. Have a good record of acquiring new generics and delivering them in a very cost effective way. No debt on the balance sheet. Great operating margins in the 35/38% range.
Generic drug manufacturer. Earnings are growing in the 20/25% range. Generics are the beneficiaries of the push to control the accelerating healthcare costs in the US. Have a good record of acquiring new generics and delivering them in a very cost effective way. No debt on the balance sheet. Great operating margins in the 35/38% range.
Laura Wallace
Managing Director, Coleford Investment Management
Price
$60.410
Owned
Yes
TOP PICK
TOP PICK
March 15, 2006
Barr Pharma is a generic manufacturer. Good match with a large cap drug company. Barr is a very good company. Strong balance sheet. Started buying at $47-48 range and are still buying.
Barr Pharma is a generic manufacturer. Good match with a large cap drug company. Barr is a very good company. Strong balance sheet. Started buying at $47-48 range and are still buying.
Laura Wallace
Managing Director, Coleford Investment Management
Price
$63.380
Owned
Yes
TOP PICK
TOP PICK
September 26, 2005
A generic manufacturer, so unlike big pharmas that suffer when things come off, they actually benefit. Just picked up Allegra which is coming off patent. A great growth vehicle with a lot of drugs coming off patent in the next several years. Great exposure in women's health products.
Barr Laboratories (BRL-N)
September 26, 2005
A generic manufacturer, so unlike big pharmas that suffer when things come off, they actually benefit. Just picked up Allegra which is coming off patent. A great growth vehicle with a lot of drugs coming off patent in the next several years. Great exposure in women's health products.
Laura Wallace
Managing Director, Coleford Investment Management
Price
$52.220
Owned
Yes
BUY
BUY
July 19, 2005
Prefers the US health care stocks as they are much larger and much more seasoned. The big pharma has been a very difficult area. A generic manufacturer. As more and more drugs come off patent, this is a good way to take advantage of the increasing demand for drugs.
Prefers the US health care stocks as they are much larger and much more seasoned. The big pharma has been a very difficult area. A generic manufacturer. As more and more drugs come off patent, this is a good way to take advantage of the increasing demand for drugs.
Laura Wallace
Managing Director, Coleford Investment Management
Price
$47.550
Owned
Yes
TOP PICK
TOP PICK
June 20, 2005
A generic drug manufacturer. Going to continue to grow at 15/20% over the next 3/5 years. There's a number of drugs coming off patent over the next 2/3 years and this company is probably the best positioned to benefit. Good price.
A generic drug manufacturer. Going to continue to grow at 15/20% over the next 3/5 years. There's a number of drugs coming off patent over the next 2/3 years and this company is probably the best positioned to benefit. Good price.
Laura Wallace
Managing Director, Coleford Investment Management
Price
$48.920
Owned
Yes
BUY WEAKNESS
BUY WEAKNESS
July 17, 2003
Generic drugs is a great sector. Accumulate on a gradual basis.
Generic drugs is a great sector. Accumulate on a gradual basis.
Brad Willock
Vice President and Senior Portfolio Manager, RBC Asset Management
Price
$63.730
Owned
Unknown
DON'T BUY
DON'T BUY
April 10, 2002
Health sector has been under a lot of pressure. Prefers specialty pharmaceuticals.
Health sector has been under a lot of pressure. Prefers specialty pharmaceuticals.
Noah Blackstein, B.A., CFA
Prtf Mngr (Goodman & Company, Investment Counsel), Dynamic Funds
Price
$67.650
Owned
Unknown
Showing 1 to 11 of 11 entries
  • «
  • 1
  • »